Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Overview of attention for article published in Frontiers in Pharmacology, August 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

So far, Altmetric has seen 1 X post from an account with 5,774 followers.

New Research: Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation https://t.co/NsUCaBdcVb #pharmacology

26 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.